|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
European stocks extended gains Thursday as investors continued to ride the global market equity rally amid a string of solid corporate earnings and renewed takeover activity.
Johnson & Johnson will purchase Swiss biotech Actelion Pharmaceuticals for $30 billion, and it plans to spin out the company's research and development unit into a separate business.
Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.
Jim Cramer wonders whether someone at Johnson & Johnson is now willing to pay more for Actelion, or if there was more give from the other side.
Actelion's CEO has held control at the company he founded, but its largest shareholder has ties with Johnson & Johnson.
U.S. stock futures post slight losses as investors await data on U.S. growth and durable goods; Carl Icahn is named special adviser to President-elect Donald Trump on overhauling federal regulations.
Shares in the biotech firm hit a record high Thursday after confirming 'exclusive' talks with Johnson & Johnson.
European stocks are likely to post modest losses Thursday as a slower holiday trading pace takes over regional markets.
The Dow Jones Industrial Average's steady path to its 20,000 milestone hit the pause button on Wednesday after a meandering day of slight losses.
Stocks hold slightly lower on Wednesday as the Dow Jones Industrial Average hovers around 40 points below its 20,000 milestone.
The Swiss biotech says it's in exclusive talks with J&J about a possible 'strategic transaction.'
Shares in the Swiss biotech surge amid reports that Sanofi could use a 'CVR' technique to enhance the potential bid price.
U.S. stock futures are mixed ahead of a decision on interest rates and fresh economic forecasts from the Fed; tech giants meet with Donald Trump; IBM's Rometty promises jobs.
Actelion confirms the end of talks with J&J over a $27 billion takeover, and market focus shifts to France's Sanofi.
European stocks are set to open lower Wednesday ahead of the Fed's final policy meeting of 2016.
U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.
European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.
Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.
Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.
The Dow trades at an all-time high Monday as the financial and energy sectors rise.
The Dow trades at an all time high Monday as crude oil climbs higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.
Stock futures rise Monday as crude oil continues to climb higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.
U.S. stock futures point higher following a decisive win for the 'No' campaign in Italy's constitutional referendum Sunday and the pending resignation of Prime Minister Matteo Renzi.
European stocks ended Tuesday's session with modest gains, although the FTSE 100 drifted lower amid the global oil selloff.
Oil prices tumble Tuesday on doubts that OPEC can reach an agreement to cut production; U.S. stock futures point to a mild rebound for Wall Street.
European stocks were mixed across the region but improving U.S. futures prices could turn the Tuesday tide.
Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.